RELEVANT EVENT

Pursuant to the provisions of article 82 of the Spanish Securities Market Act (Ley del Mercado de Valores) Grifols, S.A. ("Grifols") hereby informs about the subscription to a capital increase of the company Kiro Robotics, S.L. ("Kiro Robotics") for an amount of EUR 21 million, which represents 50% of the voting and economic rights of Kiro Robotics. The capital increase has been paid by means of a monetary contribution.

Grifols has also entered into a joint venture & shareholders' agreement (the "Joint Venture Agreement") with Kiro Robotics' partners: Mondragon Innovacion S.P.E., S.A.; Mondragon Assembly, S.Coop.; Agrupación de Fundición y Utillaje, S.Coop.. This agreement governs, among other matters, the capital increase subscribed by Grifols and the managing and governing bodies of Kiro Robotics, whether these are the Board of Directors or any other internal managing and governing bodies.

The Joint Venture foresees that the shareholders shall comply with a lock-up period of 4 years from the signing of the Joint Venture Agreement. At the end of this period, any transfer of shares will be subject to the usual limitations in this kind of transactions, including call or put options, preferential acquisition rights, and tag-along and drag-along rights.

Kiro Robotics is a Spanish company with registered office in Mondragon/Arrasate, Guipúzcoa, founded in 2011 as a spin-off of the Corporación Mondragon medical division. Kiro Robotics develops technologies that improve the efficiency, safety and service quality in the compounding of intravenous medication in hospital pharmacies. Its product, Kiro Oncology, means that a new generation of robots is able to automatically prepare intravenous medication for chemotherapy treatments. It is also equipped with a self-cleaning system, unique in this type of instrument. The automation process reduces the margin of error in the preparation of medication and minimizes the practitioners' physical contact with highly hazardous products.

In addition to marketing these products worldwide, from January 2016 Grifols will directly distribute them in Spain, Portugal and Latin America.

Currently, Kiro has a multidisciplinary team of 25 experienced professionals in automation, engineering and hospital pharmacy, dedicated to the development, validation and manufacturing of new products and applications in this field and also to customer servicing.
This transaction shows the commitment of Grifols to the research and development of its Hospital Division.

In Barcelona, on 19 September 2014

Raimon Grifols Roura
Secretary to the Board of Directors